MD1152Z - Метод определения степени тяжести гастроэзофагеальной рефлюксной болезни - Google Patents
Метод определения степени тяжести гастроэзофагеальной рефлюксной болезни Download PDFInfo
- Publication number
- MD1152Z MD1152Z MDS20160127A MDS20160127A MD1152Z MD 1152 Z MD1152 Z MD 1152Z MD S20160127 A MDS20160127 A MD S20160127A MD S20160127 A MDS20160127 A MD S20160127A MD 1152 Z MD1152 Z MD 1152Z
- Authority
- MD
- Moldova
- Prior art keywords
- sensations
- yes
- days
- day
- unpleasant
- Prior art date
Links
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 11
- 206010067171 Regurgitation Diseases 0.000 claims abstract description 26
- 208000024891 symptom Diseases 0.000 claims abstract description 15
- 206010013952 Dysphonia Diseases 0.000 claims abstract description 10
- 206010028813 Nausea Diseases 0.000 claims abstract description 8
- 230000008693 nausea Effects 0.000 claims abstract description 8
- 206010008479 Chest Pain Diseases 0.000 claims abstract description 7
- 206010014020 Ear pain Diseases 0.000 claims abstract description 7
- 230000004580 weight loss Effects 0.000 claims abstract description 7
- 210000001015 abdomen Anatomy 0.000 claims abstract description 6
- 230000007170 pathology Effects 0.000 claims abstract description 5
- 230000008673 vomiting Effects 0.000 claims abstract description 4
- 230000035807 sensation Effects 0.000 claims description 56
- 235000019615 sensations Nutrition 0.000 claims description 56
- 201000006549 dyspepsia Diseases 0.000 claims description 28
- 230000003203 everyday effect Effects 0.000 claims description 20
- 208000024798 heartburn Diseases 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 230000002354 daily effect Effects 0.000 claims description 16
- 230000009747 swallowing Effects 0.000 claims description 15
- -1 antispasmodics Substances 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 206010039424 Salivary hypersecretion Diseases 0.000 claims description 9
- 230000003628 erosive effect Effects 0.000 claims description 9
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 8
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 8
- 206010011224 Cough Diseases 0.000 claims description 7
- 229940069428 antacid Drugs 0.000 claims description 7
- 239000003159 antacid agent Substances 0.000 claims description 7
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 7
- 239000000612 proton pump inhibitor Substances 0.000 claims description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 6
- 241000234282 Allium Species 0.000 claims description 6
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 6
- 240000002234 Allium sativum Species 0.000 claims description 6
- 206010003497 Asphyxia Diseases 0.000 claims description 6
- 235000002566 Capsicum Nutrition 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 6
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 6
- 239000006002 Pepper Substances 0.000 claims description 6
- 235000016761 Piper aduncum Nutrition 0.000 claims description 6
- 235000017804 Piper guineense Nutrition 0.000 claims description 6
- 235000008184 Piper nigrum Nutrition 0.000 claims description 6
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 claims description 6
- 240000003768 Solanum lycopersicum Species 0.000 claims description 6
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 6
- AFKDOBHQNHKDEE-UHFFFAOYSA-I aluminum;magnesium;ethyl 4-aminobenzoate;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3].CCOC(=O)C1=CC=C(N)C=C1 AFKDOBHQNHKDEE-UHFFFAOYSA-I 0.000 claims description 6
- 229940125717 barbiturate Drugs 0.000 claims description 6
- 238000005452 bending Methods 0.000 claims description 6
- 235000014171 carbonated beverage Nutrition 0.000 claims description 6
- 235000019219 chocolate Nutrition 0.000 claims description 6
- 235000020971 citrus fruits Nutrition 0.000 claims description 6
- 235000016213 coffee Nutrition 0.000 claims description 6
- 235000013353 coffee beverage Nutrition 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 6
- 229960001253 domperidone Drugs 0.000 claims description 6
- 229960004770 esomeprazole Drugs 0.000 claims description 6
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 6
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001596 famotidine Drugs 0.000 claims description 6
- 235000021149 fatty food Nutrition 0.000 claims description 6
- 235000015203 fruit juice Nutrition 0.000 claims description 6
- 235000004611 garlic Nutrition 0.000 claims description 6
- 229960003174 lansoprazole Drugs 0.000 claims description 6
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 6
- 229940099076 maalox Drugs 0.000 claims description 6
- 235000013372 meat Nutrition 0.000 claims description 6
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 6
- 229960004503 metoclopramide Drugs 0.000 claims description 6
- 229960004872 nizatidine Drugs 0.000 claims description 6
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 229960000381 omeprazole Drugs 0.000 claims description 6
- 229960005019 pantoprazole Drugs 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 229960004157 rabeprazole Drugs 0.000 claims description 6
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 6
- 229960003320 roxatidine Drugs 0.000 claims description 6
- 229940125723 sedative agent Drugs 0.000 claims description 6
- 239000000932 sedative agent Substances 0.000 claims description 6
- 235000013599 spices Nutrition 0.000 claims description 6
- 239000003204 tranquilizing agent Substances 0.000 claims description 6
- 230000002936 tranquilizing effect Effects 0.000 claims description 6
- 201000007100 Pharyngitis Diseases 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 235000021270 cold food Nutrition 0.000 claims description 5
- 210000003298 dental enamel Anatomy 0.000 claims description 5
- 235000003642 hunger Nutrition 0.000 claims description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
- 244000105624 Arachis hypogaea Species 0.000 claims description 4
- 206010006326 Breath odour Diseases 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- 208000019505 Deglutition disease Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010030094 Odynophagia Diseases 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 claims description 4
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 claims description 4
- LCWAOCHOPBSGMU-UHFFFAOYSA-J aluminum;magnesium;sodium;hydrogen carbonate;oxygen(2-);silicon;trihydroxide Chemical compound [OH-].[OH-].[OH-].[O-2].[Na+].[Mg+2].[Al+3].[Si].OC([O-])=O LCWAOCHOPBSGMU-UHFFFAOYSA-J 0.000 claims description 4
- 229960003556 aminophylline Drugs 0.000 claims description 4
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 4
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 4
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 229940124575 antispasmodic agent Drugs 0.000 claims description 4
- 229940125388 beta agonist Drugs 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 4
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 4
- 229960005132 cisapride Drugs 0.000 claims description 4
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 4
- 229960003638 dopamine Drugs 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 4
- 229960003559 enprostil Drugs 0.000 claims description 4
- 229940045140 gaviscon Drugs 0.000 claims description 4
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 4
- PTOJVMZPWPAXER-VFJVYMGBSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate Chemical compound O[C@@H]1CC(=O)[C@H](CC=C=CCCC(=O)OC)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 PTOJVMZPWPAXER-VFJVYMGBSA-N 0.000 claims description 4
- 229960005249 misoprostol Drugs 0.000 claims description 4
- 239000004081 narcotic agent Substances 0.000 claims description 4
- 150000002823 nitrates Chemical class 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 229940127240 opiate Drugs 0.000 claims description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 4
- 235000020232 peanut Nutrition 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 4
- 150000003180 prostaglandins Chemical class 0.000 claims description 4
- 229960001404 quinidine Drugs 0.000 claims description 4
- SPOAFZKFCYREMW-FWYLUGOYSA-N rioprostil Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO SPOAFZKFCYREMW-FWYLUGOYSA-N 0.000 claims description 4
- 229950004712 rioprostil Drugs 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 claims description 4
- 229960004291 sucralfate Drugs 0.000 claims description 4
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims description 4
- 235000013616 tea Nutrition 0.000 claims description 4
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 3
- 206010006784 Burning sensation Diseases 0.000 claims description 3
- 208000000059 Dyspnea Diseases 0.000 claims description 3
- 206010013975 Dyspnoeas Diseases 0.000 claims description 3
- 206010015137 Eructation Diseases 0.000 claims description 3
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims description 3
- 208000032139 Halitosis Diseases 0.000 claims description 3
- 208000000616 Hemoptysis Diseases 0.000 claims description 3
- 208000010473 Hoarseness Diseases 0.000 claims description 3
- 208000037656 Respiratory Sounds Diseases 0.000 claims description 3
- 208000008630 Sialorrhea Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 206010042241 Stridor Diseases 0.000 claims description 3
- 208000025371 Taste disease Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- 208000027687 belching Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 210000000038 chest Anatomy 0.000 claims description 3
- 208000013116 chronic cough Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000007176 earache Diseases 0.000 claims description 3
- 206010016766 flatulence Diseases 0.000 claims description 3
- 210000004051 gastric juice Anatomy 0.000 claims description 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims description 3
- 208000027498 hoarse voice Diseases 0.000 claims description 3
- 235000021268 hot food Nutrition 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 210000000867 larynx Anatomy 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 235000019656 metallic taste Nutrition 0.000 claims description 3
- 230000000422 nocturnal effect Effects 0.000 claims description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 3
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 208000026451 salivation Diseases 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000004916 vomit Anatomy 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000034991 Hiatal Hernia Diseases 0.000 claims description 2
- 206010020028 Hiatus hernia Diseases 0.000 claims description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 201000003453 lung abscess Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000025644 recurrent pneumonia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 244000203593 Piper nigrum Species 0.000 claims 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 235000021259 spicy food Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 206010028836 Neck pain Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 208000016261 weight loss Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 241000722363 Piper Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 208000007217 Esophageal Stenosis Diseases 0.000 description 2
- 206010030194 Oesophageal stenosis Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000003153 cholinolytic effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012327 Endoscopic diagnosis Methods 0.000 description 1
- 208000005489 Esophageal Perforation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 206010030181 Oesophageal perforation Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000012277 endoscopic treatment Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Изобретение относится к медицине, в частности к гастроэнтерологии и может быть использовано для определения степени тяжести гастроэзофагеальной рефлюксной болезни.Сущность изобретения заключается в том, что проводят клиническое обследование с оценкой таких симптомов как загрудинные боли, регургитации, затрудненное глотание, тошнота, рвота, неприятные ощущения во рту и животе, дисфония, боль в шее и в ушах, потеря веса, сопутствующие патологии, индекс массы тела, а именно их продолжительность и экспрессия, факторы, которые их улучшают и/или ухудшают, влияние этих симптомов на качество жизни, с присвоением баллов для каждого симптома. В случае, когда сумма баллов составляет 1...70, определяют легкую степень тяжести, когда 71...129 - среднюю степень и когда она составляет 130...211, определяют тяжелую степень тяжести гастроэзофагеальной рефлюксной болезни.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20160127A MD1152Z (ru) | 2016-11-15 | 2016-11-15 | Метод определения степени тяжести гастроэзофагеальной рефлюксной болезни |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20160127A MD1152Z (ru) | 2016-11-15 | 2016-11-15 | Метод определения степени тяжести гастроэзофагеальной рефлюксной болезни |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1152Y MD1152Y (ru) | 2017-06-30 |
| MD1152Z true MD1152Z (ru) | 2018-01-31 |
Family
ID=59272845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20160127A MD1152Z (ru) | 2016-11-15 | 2016-11-15 | Метод определения степени тяжести гастроэзофагеальной рефлюксной болезни |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1152Z (ru) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1304804A1 (ru) * | 1984-09-25 | 1987-04-23 | Минский государственный медицинский институт | Способ диагностики гастроэзофагеального рефлюкса |
| SU1364347A1 (ru) * | 1985-12-10 | 1988-01-07 | Латвийский Научно-Исследовательский Институт Экспериментальной И Клинической Медицины | Способ диагностики желудочно-пищеводного рефлюкса |
| SU1380731A1 (ru) * | 1986-02-27 | 1988-03-15 | Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии | Способ определени степени выраженности желудочно-пищеводного рефлюкса с помощью рН-зондировани пищевода |
| SU1421307A1 (ru) * | 1985-05-27 | 1988-09-07 | Минский государственный медицинский институт | Способ диагностики гастроэзофагеального рефлюкса у детей |
| MD202G2 (ru) * | 1993-05-05 | 1996-01-31 | Государственный Университет Молд0 | Способ получения активного gama-MnO2 |
| MD2160G2 (ru) * | 2003-01-23 | 2003-11-30 | СКОРПАН Анатолие | Метод диагностики степени тяжести рефлюкс-эзофагита |
-
2016
- 2016-11-15 MD MDS20160127A patent/MD1152Z/ru not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1304804A1 (ru) * | 1984-09-25 | 1987-04-23 | Минский государственный медицинский институт | Способ диагностики гастроэзофагеального рефлюкса |
| SU1421307A1 (ru) * | 1985-05-27 | 1988-09-07 | Минский государственный медицинский институт | Способ диагностики гастроэзофагеального рефлюкса у детей |
| SU1364347A1 (ru) * | 1985-12-10 | 1988-01-07 | Латвийский Научно-Исследовательский Институт Экспериментальной И Клинической Медицины | Способ диагностики желудочно-пищеводного рефлюкса |
| SU1380731A1 (ru) * | 1986-02-27 | 1988-03-15 | Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии | Способ определени степени выраженности желудочно-пищеводного рефлюкса с помощью рН-зондировани пищевода |
| MD202G2 (ru) * | 1993-05-05 | 1996-01-31 | Государственный Университет Молд0 | Способ получения активного gama-MnO2 |
| MD2160G2 (ru) * | 2003-01-23 | 2003-11-30 | СКОРПАН Анатолие | Метод диагностики степени тяжести рефлюкс-эзофагита |
Non-Patent Citations (4)
| Title |
|---|
| American gastroenterological association. Medical Position Statement: Guidelines on the Use of Esophageal pH. Gastroenterology, 1996, vol.110, p.1981-1996 * |
| Hunter J.G., Trus T.L., Branum G.D., Waring J.P., Wood W.C. A physiologic approach to laparoscopic fundoplication for gastroesophagel reflux disease. Ann. surg., 1996, nr. 223, p. 673-685 * |
| Katz P. O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J. Gastroenterol., 2013, nr. 108, p. 308-328 * |
| Position Statement: Guidelines on the Use of Esophageal pH. Gastroenterology, 1996, vol.110, p.1981-1996. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD1152Y (ru) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fass et al. | Gastro-oesophageal reflux disease | |
| Iwakiri et al. | Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015 | |
| Richter | Typical and atypical presentations of gastroesophageal reflux disease: the role of esophageal testing in diagnosis and management | |
| Mcnally et al. | Evaluation of gastroesophageal reflux as a cause of idiopathic hoarseness | |
| Bortolotti | Laryngospasm and reflex central apnoea caused by aspiration of refluxed gastric content in adults. | |
| Roesch-Ramos et al. | Dental erosion, an extraesophageal manifestation of gastroesophageal reflux disease. The experience of a center for digestive physiology in Southeastern Mexico | |
| Issing et al. | Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux | |
| Wong et al. | Gastro-esophageal reflux disease in children | |
| Jiang et al. | Antireflux action of Nissen fundoplication and stretch-sensitive mechanism of lower esophageal sphincter relaxation | |
| MD1152Z (ru) | Метод определения степени тяжести гастроэзофагеальной рефлюксной болезни | |
| Siegel et al. | Respiratory complications of gastroesophageal reflux disease | |
| Aradya et al. | Gastroesophageal Reflux Disease (GERD)–Role of Dentist | |
| Liu et al. | Difference of esophageal motility and reflux characteristics in patients with gastroesophageal reflux disease (GERD) and chronic cough (CC) and the impact of standardized drug therapy | |
| Watson et al. | Reflux disease | |
| Harding | Gastroesophageal reflux during sleep | |
| Woolard et al. | Gastroesophageal reflux disease | |
| Dent et al. | Gastro-oesophageal reflux disease: current concepts in management | |
| Zamir | Gastroesophageal reflux | |
| Jalal et al. | Medical treatment of gastro-oesophageal reflux disease | |
| Bogun et al. | A case of erosive gastroesophageal reflux disease | |
| Durazzo | Durazzo M, Lupi G, Cicerchia F, Ferro A, Barutta F, Beccuti G, Gruden G, Pellicano R. Extra-Esophageal Presentation of Gastroesophageal Reflux Disease: 2020 Update. Journal of clinical medicine, 2020, 9 (8), 2559. | |
| Dobrzyński et al. | Extraesophageal manifestations of gastroesophageal reflux disease–pathophysiology, diagnosis and management | |
| Oude Nijhuis | Moving forward: new insights into esophageal motility disorders | |
| de Vries et al. | W1811 Distinct Clinical and Epidemiological Features Separate GERD Patients with Physiological Esophageal Acid Exposure from Patients with Pathological Acid Exposure | |
| Thélin et al. | Gastroesophageal reflux |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |